DBV Technologies

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
DBV Technologies SA
DBV Technologies
Société Anonyme
Traded asEuronextDBV
CAC Mid 60 Component
IndustryBiotechnology
FoundedBagneux, France (2002 (2002))
Founder
  • Bertrand Dupont
  • Christophe Dupont
  • Pierre-Henri Benhamou
Headquarters,
Key people
  • Pierre-Henri Benhamou (CEO)
  • Bertrand Dupont (Senior Executive Vice President of Technology)
  • David Schilansky (CFO)
ProductsAllergy treatments, Allergy diagnosis
Websitewww.dbv-technologies.com

DBV Technologies SA is a publicly owned, French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.[1][2][3][4][5][6][7]

History[edit]

DBV Technologies was founded in 2002 by Doctor Pierre-Henri Benhamou (specializing in Pediatric Gastroenterology), the engineer Bertrand Dupont (from the Arts et Métiers ParisTech in Paris) and Professor Christophe Dupont (head of the Neonatology Department Saint Vincent Hospital, Paris).[1][4][8][9][10][11]

The founders provided initial startup capital.[4] Approximately €40M in venture funding was acquired between December, 2003 and January, 2011.[3][12][13] In March 2012, an initial public offering on the NYSE Euronext exchange yielded €40.5M (Euros).[2][14][15][16]

Dr. Benhamou presently serves as CEO and Mr. Dupont as Senior Executive Vice President of Technology.[1][11]

Product[edit]

DBV Technologies is focused on food allergies (milk and peanut), and pediatric allergies for which there are currently no effective treatments.[17] It has developed two products: Viaskin Peanut for the treatment of peanut allergies and Viaskin Milk for cow's milk allergies.[5][6][18]

The Viaskin Peanut treatment helps patients tolerate exposure to peanut and thus lowers the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen.[1][4][5][18]

The clinical development program for Viaskin Peanut has received "Fast Track" designation from the US Food and Drug Administration. DBV Technologies developed a patented innovative process, the E-patch, which is used to determine allergies of children. The ready-to-use standardised patch tests are highly reliable and conserve the allergic agents in their best state of allergy.[7][17][19] In September 2014, DBV Technologies announced that its VIPES (Viaskin Peanut Efficacy and Safety) clinical trial of Viaskin Peanut achieved successful results in peanut allergy desensitization.[20]

References[edit]

  1. ^ a b c d "DBV Technologies SA". Bloomberg. Retrieved February 8, 2013.
  2. ^ a b Albertina Torsoli (March 28, 2012). "Paris Is Europe Health IPO Hub With Most Sales in 20 Years". Bloomberg Businessweek. Archived from the original on March 31, 2012. Retrieved February 8, 2013.
  3. ^ a b "DBV Technologies". CrunchBase. Retrieved February 8, 2013.
  4. ^ a b c d "Presentation". DBV Technologies. Retrieved February 8, 2013.
  5. ^ a b c "DBV Technologies and Centre d'Immunologie de Marseille-Luminy (CIML) enter in a Collaboration Agreement". FierceBiotech. Retrieved February 8, 2013.
  6. ^ a b "Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy (VIPES)". ClinicalTrials. Retrieved February 8, 2013.
  7. ^ a b Marie Powers (January 16, 2013). "DBV Seeks Immunotherapeutic to Desensitize Food Allergies". BioWorld. Retrieved February 8, 2013.
  8. ^ "Pierre-Henri Benhamou, DBV Technologies". Global Intellectual Property Center. Retrieved February 8, 2013.
  9. ^ "DBV Technologies initiates VIPES phase IIb clinical study, the first global trial ever in desensitization of peanut-allergic children and adults". Evaluate Pharma. August 2, 2012. Retrieved February 8, 2013.
  10. ^ Heather Legg. "Peanut Allergy Patch". Beyond Allergy. Retrieved February 8, 2013.
  11. ^ a b "Management". DBV Technologies. Retrieved February 8, 2013.
  12. ^ "DBV Technologies closes $25.5m financing round". MTB Europe. February 7, 2011. Retrieved February 8, 2013.
  13. ^ "DBV Technologies secures $25.5 million in Series C financing round". News Medical. January 5, 2011. Retrieved February 8, 2013.
  14. ^ "Successful Initial Public Offering (IPO) for DBV Technologies on the NYSE Euronext regulated market in Paris. DBV Technologies raises € 40.5 million". Lundbeckfond Ventures. March 28, 2012. Retrieved February 8, 2013.
  15. ^ "NYSE Euronext welcomes DBV Technologies to its European market". NYSE Euronext. March 29, 2012. Archived from the original on June 7, 2012. Retrieved February 8, 2013.
  16. ^ "Sofinnova Partners' portfolio company DBV Technologies successfully raises €40.5M in its oversubscribed IPO". Sofinnova. March 29, 2012. Retrieved February 8, 2013.[permanent dead link]
  17. ^ a b "DBV Technologies launches its third Viaskin® program, a first for the treatment of House Dust Mites (HDM) allergy in young children". Biotechnology Industry Organization. November 14, 2012. Archived from the original on April 14, 2013. Retrieved February 8, 2013.
  18. ^ a b "Division of Allergy and Immunology" (PDF). Chicago Childrens Research. Retrieved February 8, 2013.
  19. ^ "Skin patch could cure peanut allergy". The Daily Telegraph. May 30, 2011. Retrieved February 8, 2013.
  20. ^ "DBV Technologies Announces Primary Endpoint Met in VIPES, Viaskin Peanut's Phase IIb Clinical Trial in Peanut Allergy". 22 September 2014. Retrieved 28 October 2014.

External links[edit]